000			01961 a2200517 4500
005			20250515051210.0
264		0	_c20070223
008			200702s 0 0 eng d
022			_a0953-816X
024	7		_a10.1111/j.1460-9568.2006.05192.x _2doi
040			_aNLM _beng _cNLM
100	1		_aAnderson, David W
245	0	0	_aNeuroprotection in Parkinson models varies with toxin administration protocol. _h[electronic resource]
260			_bThe European journal of neuroscience _cDec 2006
300			_a3174-82 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_a1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aAntigens, Nuclear _xmetabolism
650	0	4	_aAxons _xdrug effects
650	0	4	_aBenzothiazoles _xpharmacology
650	0	4	_aBiomarkers _xmetabolism
650	0	4	_aCorpus Striatum _xdrug effects
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine _xmetabolism
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Evaluation, Preclinical _xmethods
650	0	4	_aMPTP Poisoning _xphysiopathology
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aNerve Degeneration _xchemically induced
650	0	4	_aNerve Tissue Proteins _xmetabolism
650	0	4	_aNeurons _xdrug effects
650	0	4	_aNeuroprotective Agents _xpharmacology
650	0	4	_aNiacinamide _xpharmacology
650	0	4	_aParkinsonian Disorders _xchemically induced
650	0	4	_aPramipexole
650	0	4	_aSubstantia Nigra _xdrug effects
650	0	4	_aTyrosine 3-Monooxygenase _xmetabolism
700	1		_aBradbury, Kristin A
700	1		_aSchneider, Jay S
773	0		_tThe European journal of neuroscience _gvol. 24 _gno. 11 _gp. 3174-82
856	4	0	_uhttps://doi.org/10.1111/j.1460-9568.2006.05192.x _zAvailable from publisher's website
999			_c16725363 _d16725363